What is the price target for EXE stock?
10 analysts have analysed EXE.CA and the average price target is 28.52 CAD. This implies a price decrease of -1.02% is expected in the next year compared to the current price of 28.81.
EXTENDICARE INC (EXE.CA) Forecast, Price Target & Analyst Ratings
TSX:EXE • CA30224T8639
Current stock price
28.81 CAD
+0.47 (+1.66%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EXTENDICARE INC (EXE.CA).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
CA$28.52
Upside
-1.02%
From current price of CA$28.81 to mean target of CA$28.52, Based on 10 analyst forecasts
Low
CA$19.19
Median
CA$30.60
High
CA$36.75
Price Target Revisions
1 Month
16.74%
3 Months
16.67%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for EXE.CA. The average price target is 28.52 CAD. This implies a price decrease of -1.02% is expected in the next year compared to the current price of 28.81.
The average price target has been revised upward by 16.67% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
78.00%
EXE.CA was analyzed by 10 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about EXE.CA.
In the previous month the buy percentage consensus was at a similar level.
EXE.CA was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-11-17 | RBC Royalbank | Downgrade | Sector Perform |
| 2022-10-24 | National Bank of Canada Financial | Downgrade | |
| 2022-10-20 | TD Research | Downgrade | Strong Buy |
| 2022-06-27 | CIBC Capital Markets | Downgrade | Neutral |
| 2022-03-03 | RBC Royalbank | Upgrade | Sector Perform |
| 2022-02-28 | CIBC Capital Markets | Upgrade | Neutral |
| 2022-02-07 | TD Research | Initiate | Hold |
| 2022-02-07 | TD Securities | Initiate | Hold |
| 2021-11-15 | RBCRoyalBank | Downgrade | Sector Perform |
| 2021-11-09 | Laurentian Banks | Maintains | Hold |
| 2021-11-09 | Laurentian Bank | Maintains | Hold |
| 2021-11-08 | CIBC WG | Maintains | Neutral |
| 2021-11-08 | TDNewcrest | Downgrade | Hold |
| 2021-11-08 | CM Bank | Maintains | Neutral |
| 2021-11-08 | Laurentian Bank | Downgrade | |
| 2021-11-01 | CIBC World Markets | Maintains | Neutral |
| 2021-10-01 | TD Securities | Downgrade | Hold |
| 2021-08-11 | National Bank Financial | Downgrade | Outperform |
| 2021-08-09 | Laurentian Bank | Upgrade | |
| 2021-07-19 | National Bank Financial | Upgrade | |
| 2021-05-21 | RBC Capital | Upgrade | Sector Perform |
| 2021-05-18 | Laurentian Bank | Upgrade | Hold |
| 2021-05-18 | National Bank Financial | Upgrade | Sector Perform |
| 2021-05-17 | National Bank Financial | Upgrade | |
| 2021-05-14 | TD Securities | Upgrade | Hold |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2026 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.305B 6.83% | 1.466B 12.36% | 1.66B 13.25% | 2.217B 33.52% | 2.395B 8.03% | 2.452B 2.38% | |
| EBITDA YoY % growth | 95.187M 64.06% | 144.549M 51.86% | 175.614M 21.49% | 218.83M 24.61% | 252.88M 15.56% | 260.8M 3.13% | |
| EBIT YoY % growth | 62.962M 143.14% | 111.213M 76.64% | 138.671M 24.69% | 1.444M -98.96% | 229.78M 15,812.74% | 241.34M 5.03% | |
| Operating Margin | 4.82% | 7.59% | 8.35% | 0.07% | 9.59% | 9.84% | |
| EPS YoY % growth | N/A 378.57% | N/A 135.82% | N/A 31.96% | 1.14 8.39% | 1.34 17.70% | 1.49 11.28% |
All data in CAD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in CAD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.39%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
13.52%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
19.17%
EBIT Next 5 Year
N/A
EXTENDICARE INC / EXE.CA Forecast FAQ
What is the next earnings date for EXE stock?
EXTENDICARE INC (EXE.CA) will report earnings on 2026-05-04.
Can you provide the analyst count for EXTENDICARE INC stock?
The number of analysts covering EXTENDICARE INC (EXE.CA) is 10.